QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial ; volume:131 ; number:4 ; day:21 ; month:6 ; year:2024 ; pages:668-675 ; date:9.2024
British journal of cancer ; 131, Heft 4 (21.6.2024), 668-675, 9.2024
- Urheber
-
Zuo, Wenjia
Wang, Zhonghua
Qian, Jun
Ma, Xiaopeng
Niu, Zhaofeng
Ou, Jianghua
Mo, Qinguo
Sun, Jing
Li, Xinzheng
Wang, Qitang
Yao, Yongzhong
Yu, Guohua
Li, Hongsheng
Chen, Dedian
Zhang, Hao
Geng, Cuizhi
Qiao, Guangdong
Zhao, Mengmeng
Zhang, Baihui
Kang, Xiaoyan
Zhang, Jin
Shao, Zhimin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-024-02751-2
- URN
-
urn:nbn:de:101:1-2411052112320.859267022210
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zuo, Wenjia
- Wang, Zhonghua
- Qian, Jun
- Ma, Xiaopeng
- Niu, Zhaofeng
- Ou, Jianghua
- Mo, Qinguo
- Sun, Jing
- Li, Xinzheng
- Wang, Qitang
- Yao, Yongzhong
- Yu, Guohua
- Li, Hongsheng
- Chen, Dedian
- Zhang, Hao
- Geng, Cuizhi
- Qiao, Guangdong
- Zhao, Mengmeng
- Zhang, Baihui
- Kang, Xiaoyan
- Zhang, Jin
- Shao, Zhimin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Addendum zum Auftrag A13-10 (Pertuzumab)
Pertuzumab: Nutzenbewertung gemäß § 35a SGB V
Pertuzumab: Addendum zum Auftrag A15-34
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert / lokal rezidiviert; in Kombination mit Docetaxel) : Nutzenbewertung gemäß § 35a SGB V
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Addendum zum Auftrag A13-10 (Pertuzumab)
Pertuzumab: Nutzenbewertung gemäß § 35a SGB V
Pertuzumab: Addendum zum Auftrag A15-34
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert / lokal rezidiviert; in Kombination mit Docetaxel) : Nutzenbewertung gemäß § 35a SGB V
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Addendum zum Auftrag A13-10 (Pertuzumab)
Pertuzumab: Nutzenbewertung gemäß § 35a SGB V
Pertuzumab: Addendum zum Auftrag A15-34
A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects
Pertuzumab/Trastuzumab (Mammakarzinom, metastasiert / lokal rezidiviert; in Kombination mit Docetaxel) : Nutzenbewertung gemäß § 35a SGB V